Search
Selected Filter
Displaying 1–10 of 204 diseases results
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
Research NewsThe expanded Phase 1/2/3 shortens time to potential FDA approval.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
Turning RP into a Canvas of Hope
Beacon StoriesDiagnosed with retinitis pigmentosa (RP) at 12, Raquel spent years navigating vision loss without support. But everything changed when she connected with the Foundation Fighting Blindness — and found not just answers, but community. Now an artist, advocate, and leader in San Diego, Raquel uses her story and her art as the founder of Unblurred Collection to raise awareness, give back, and inspire others living with blinding diseases.
-
Eye on the Cure Podcast | Episode 87: Dr. Philip Beales
Eye on the CureDr. Philip Beales, a co-founder of Axovia Therapeutics, talks about Bardet Biedl syndrome.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Legacy Donor Spotlight: Dr. Debora Elliott Ward
Beacon StoriesDr. Debora Elliott Ward, a clinical psychologist living with retinitis pigmentosa, shares her journey of resilience, professional success, and commitment to supporting the Foundation Fighting Blindness by naming it a beneficiary in her estate plans.
-
Invisible Disability
I find it difficult to explain my eyesight to people. I have retinitis pigmentosa (RP), which is a condition that progressively causes vision loss. I am legally blind, my peripheral vision is very limited, and most of what I see is blurry.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
.png)
